(Q34515547)

2 August 2017

1 reference

title

Pancreatic cancer: the evolving role of systemic therapy (English)

1 reference

ORCID Public Data File 2021

2 August 2017

1 reference

1 reference

author name string

N V Adsay

series ordinal

1

1 reference

2 August 2017

B F El-Rayes

series ordinal

2

1 reference

2 August 2017

P A Philip

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

Expert Opinion on Pharmacotherapy

2 August 2017

published in

1 reference

2 August 2017

volume

2

1 reference

2 August 2017

issue

12

1 reference

2 August 2017

page(s)

1939-1947

1 reference

Prognostic indicators for survival after resection of pancreatic adenocarcinoma.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1939

Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1939

Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1939

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1939

Phase II study of gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1939

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1939

Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1939

Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1939

Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1939

Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1939

Intracellular unesterified arachidonic acid signals apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1939

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1939

Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1939

Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1939

Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1939

10.1517/14656566.2.12.1939

21 January 2018

Identifiers

DOI

1 reference

release_wakc5coyirhglaijcns4clqwji

2 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wakc5coyirhglaijcns4clqwji

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference